Navigation Links
MultiCell Technologies Relocates Corporate Headquarters
Date:5/2/2008

WOONSOCKET, R.I., May 2 /PRNewswire-FirstCall/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has moved into new space and will have a different address and telephone numbers. Effective May 1, 2008:

-- the new address is: 68 Cumberland Street, Suite 301, Woonsocket,

RI 02895.

-- new phone number is: (401) 762-0045

-- the new fax number is: (401) 762-0098

MultiCell Technologies, Inc. is a biopharmaceutical company developing new therapeutics including:

MCT-125 for the treatment of primary fatigue in MS patients.

MCT-175 for the treatment of relapsing-remitting MS.

MCT-465 for the treatment of TLR3 positive breast cancers.

MCT-475 for the treatment of TLR3 positive cervical cancers.

MultiCell also sells and/or licenses immortalized human liver cells to the pharmaceutical industry and holds patents on the Sybiol(R) synthetic bio-liver device and liver-derived adult human stem cells.

For more information about MultiCell Technologies, please visit http://www.multicelltech.com .

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could," and "would." Examples of such forward looking statements include statements regarding the timing, design, scope, and anticipated results of our clinical development programs. MultiCell bases these forward- looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2007, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.


'/>"/>
SOURCE MultiCell Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
2. MultiCell Technologies To Increase Focus on Therapeutic Candidates
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
7. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
8. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
9. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
10. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... ... Doctors in Italy, Japan, the UK and the US have reached some ... and its link to malignant mesothelioma. Surviving Mesothelioma has just posted the details of ... , The studies analyzed for the new report included more than 3,447 cancer ...
(Date:5/27/2016)... , May 27, 2016 At ... investors playing in this space know that volatility is what ... featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: ... Lpath Inc. (NASDAQ: LPTN ), and Heat Biologics ... gain access to the technical alerts for these stocks at: ...
(Date:5/26/2016)... Jersey and READING, England ... Indegene ( http://www.indegene.com ), a leading global ... life science, pharmaceutical and healthcare organisations and TranScrip ... innovative scientific support throughout the product lifecycle, today ... the launch of IntraScience.      (Logo: ...
(Date:5/26/2016)... , May 26, 2016 Despite the ... value in this space. Today,s pre-market research on ActiveWallSt.com directs ... Health Inc. (NASDAQ: RDUS ), Cerus Corp. (NASDAQ: ... ARWR ), and Five Prime Therapeutics Inc. (NASDAQ: ... briefings at: http://www.activewallst.com/ On ...
Breaking Biology Technology:
(Date:3/15/2016)... March 15, 2016 --> ... by Transparency Market Research "Digital Door Lock Systems Market - ... - 2023," the global digital door lock systems market in ... 2014 and is forecast to grow at a CAGR of ... small and medium enterprises (MSMEs) across the world and high ...
(Date:3/11/2016)... , March 11, 2016 ... market research report "Image Recognition Market by Technology (Pattern ... and Advertising), by Deployment Type (On-Premises and Cloud), by ... 2022", published by MarketsandMarkets, the global market is expected ... USD 29.98 Billion by 2020, at a CAGR of ...
(Date:3/9/2016)... BEACH GARDENS, Fla. , March 9, 2016 ... identity management authentication and enrollment solutions, today announced ... DigitalPersona ® Altus multi-factor authentication ... IT and InfoSec managers to step-up security where ... Washington, DC . ...
Breaking Biology News(10 mins):